Research chemical comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-09-17. Numbers and descriptions here follow the published literature rather than marketing material.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA as a metabolic modulator. |
| Approved medical use | None in major jurisdictions | Not a registered drug. |
| Common test matrix | Urine | Most anti-doping samples use urine. |
| Typical detection method | LC-MS/MS | Detects parent compound and metabolites. |
| Reference standard storage | -20 °C, desiccated | Typical for analytical standards. |
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Sutherland and colleagues have proposed that phosphorimidazolides may have formed in the chemical environment of early Earth via the activation of ribonucleotide phosphates by methyl isocyanaide and acetaldehyde followed by substitution with imidazole.
The epithelium is the innermost layer. It is where most digestive, absorptive and secretory processes occur. The lamina propria, the underlying layer of loose connective tissue within the mucosa. The muscularis mucosae, a thin layer of smooth muscle. The epithelium, the most exposed part of the mucosa, is a glandular epithelium with many goblet cells. Goblet cells secrete mucus, which lubricates the passage of food along and protects the intestinal wall from digestive enzymes. In the small intestine, villi are folds of the mucosa that increase the surface area of the intestine. The villi contain a lacteal, a vessel connected to the lymph system that aids in the removal of lipids and tissue fluids. Microvilli are present on the epithelium of a villus and further increase the surface area over which absorption can take place. Numerous intestinal glands as pocket-like invaginations are present in the underlying tissue. In the large intestines, villi are absent and a flat surface with thousands of glands is observed. Underlying the epithelium is the lamina propria, which contains myofibroblasts, blood vessels, nerves, and several different immune cells, and the muscularis mucosa which is a layer of smooth muscle that aids in the action of continued peristalsis and catastalsis along the gut.
There are several other Psilocybe species that may be confused with P. semilanceata due to similarities in physical appearance. P. strictipes is a slender grassland species that is differentiated macroscopically from P. semilanceata by the lack of a prominent papilla. P. mexicana, commonly known as the "Mexican liberty cap", is also similar in appearance, but is found in manure-rich soil in subtropical grasslands in Mexico. It has somewhat smaller spores than P. semilanceata, typically 8–9.9 by 5.5–7.7 μm. Another lookalike species is P. samuiensis, found in Thailand, where it grows in well-manured clay-like soils or among paddy fields. This mushroom can be distinguished from P. semilanceata by its smaller cap, up to 1.5 cm (0.6 in) in diameter, and its rhomboid-shaped spores. P. pelliculosa is physically similar to such a degree that it may be indistinguishable in the field. It differs from P. semilanceata by virtue of its smaller spores, measuring 9–13 by 5–7 μm. P. semilanceata has also been confused with the toxic muscarine-containing species Inocybe geophylla, a whitish mushroom with a silky cap, yellowish-brown to pale grayish gills, and a dull yellowish-brown spore print.
Sources: en.wikipedia.org
Kwäday Dän Ts'ìnchi ("Long ago person found" in the Southern Tutchone language of the Champagne and Aishihik First Nations), was found in August 1999 by three First Nations hunters at the edge of a glacier in Tatshenshini-Alsek Provincial Park, British Columbia, Canada. According to the Kwäday Dän Ts'ìnchi Project, the remains are the oldest well preserved mummy discovered in North America. (The Spirit Cave mummy although not well preserved, is much older.) Initial radiocarbon tests date the mummy to around 550 years-old.
=== Surgery === A 2024 review found that surgical patients with metabolic syndrome had higher risk of death, surgical site infection, cardiovascular complications, hospital readmission, and longer hospitalization compared with those without the condition. Interventions for reducing surgical complications in people with metabolic syndrome are absent, indicating a need for preoperative screening, surgical prehabilitation, and improved monitoring, management, and postoperative care. Metabolic (bariatric) surgery is considered when lifestyle and pharmacotherapy are insufficient. Surgery is associated with durable weight loss and partial or complete remission of type 2 diabetes, hypertension, and dyslipidaemia. Guidelines endorse surgery for BMI ≥35 kg/m², or ≥30 kg/m² with metabolic complications.
In 1895, Vincenzo Tiberio, an Italian physician at the University of Naples, published research on moulds initially found in a water well in Arzano; from his observations, he concluded that these moulds contained soluble substances having antibacterial action. A Pasteur Institute scientist, Costa Rican Clodomiro Picado Twight, similarly recorded the antibiotic effect of Penicillium in 1923. In these early stages of penicillin research, most species of Penicillium were non-specifically referred to as P. glaucum, so that it is impossible to know the exact species and that it was really penicillin that prevented bacterial growth. André Gratia and Sara Dath at the Free University of Brussels studied the effects of bacterial samples on other bacteria. In 1924, they found that dead Staphylococcus aureus cultures were contaminated by a streptomycete. Upon further experimentation, they showed that an extract of the streptomycete could kill not only S. aureus, but also Pseudomonas aeruginosa, Mycobacterium tuberculosis and Escherichia coli (E. coli). Gratia called the antibacterial agent "mycolysate". The next year they found a killer mould that could inhibit B. anthracis. Reporting in Comptes rendus des séances de la Société de Biologie et de ses filiales, they identified the mould as Penicillium glaucum. These findings, however, received little attention as the antibacterial agent and its medical value were not fully understood, and Gratia's samples were lost.
Sources: en.wikipedia.org
Legal status varies by country, but cardarine is not approved as a medicine in major jurisdictions. It is often sold as a research chemical, a category that may not be lawful for human use. Buyers should check local laws and product labels carefully.
Anti-doping laboratories use LC-MS/MS to detect GW501516 and its metabolites, usually in urine. The method can identify the parent compound at low concentrations. Detection windows vary with dose and individual factors.
No, cardarine has no approved medical uses in major jurisdictions. Early research explored metabolic conditions, but those programs were discontinued. It is not a registered treatment for any disease.
Cardarine is an investigational synthetic compound that acts as a PPARδ agonist. It is also known as GW501516 and has been studied mainly in preclinical research. It is not an approved medicine.